‘Tell me we’re winning the media battle!’ I imagine Unilever boss Alan Jope barking at his team on Tuesday, following the revelation on Sunday of his rejected £50 billion bid for GlaxoSmithKline’s consumer healthcare arm.
‘Yes, sir,’ replies the flustered PR, ‘Very much so… except for top investor Richard Buxton of Jupiter telling the FT: “The idea of letting the goons at Unilever run [the GSK business] is laughable.” Then there’s an analyst in the Telegraph saying: “We can’t imagine many things that would unnerve us more about Unilever” than this deal going ahead. Oh, and our shares fell 7 per cent yesterday.’
Jope is now huddled with his advisers trying to work out whether he can up his bid to the £60 billion that might be acceptable to GSK shareholders without crippling his own balance sheet. And if he does so, will the market accept that Unilever —widely seen as a top-heavy conglomerate struggling to extract decent returns from its existing soap-to-ice-cream portfolio — is capable of turning a profit from the acquisition of another big bundle of GSK brands?
In the end, price always trumps logic in the takeover arena.
Get Britain's best politics newsletters
Register to get The Spectator's insight and opinion straight to your inbox. You can then read two free articles each week.
Already a subscriber? Log in
Comments
Join the debate for just £1 a month
Be part of the conversation with other Spectator readers by getting your first three months for £3.
UNLOCK ACCESS Just £1 a monthAlready a subscriber? Log in